BCRX - BioCryst Projected Sales Volume
Complex targeted drug delivery for rare pathologies puts pressure on the budget, which is evident in the volatility of BioCryst (BCRX) sales forecasts. The 0.96 metric reflects current dynamics, where optimization is driven by the high-margin ORLADEYO tablets. Stable management at BioCryst is steering the business toward net profit, smoothing out the market noise on the chart.
Summary analytical data breakdowns for BioCryst Pharmaceuticals, Inc. (BCRX)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization information:
- debt level and financial liquidity data:
Debt to Equity BioCryst|BCRX - Long-Term Liabilities to Capital|Short-Term Debt to Capital BioCryst Pharmaceuticals Inc|BCRX - Company Total Debt|Debt to Book Capitalization Ratio BioCryst Pharmaceuticals, Inc.|BCRX - Company Long-Term Loans and Borrowings|Company Current Liabilities BioCryst|Quick Liquidity biocryst.com
- earnings and market ratios statistics:
BCRX - Net Financial Result|Future Profit BioCryst|BCRX - Market Price to Net Income Ratio|Forward P/E Multiple BioCryst Pharmaceuticals|BCRX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BioCryst Pharmaceuticals, Inc.|BCRX - Operating profit before deduction of amortization|Earnings per share for the last twelve months BioCryst|BCRX - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months biocryst.com|BCRX - Earnings per share growth this year|Net earnings per share growth forecast for next year BioCryst
- issuer revenue and sales details:
Fundamental company analysis:BCRX BioCryst
The stability of BioCryst (BCRX) depends on the efficiency of managing contract manufacturing organizations (CMO), which minimizes capital expenditures but increases operational risks. The trend in projected product sales reflects management's ability to achieve commercial goals and confirms the capital density of the asset, allowing investors to identify strategic deviations or signs of reporting manipulation through daily monitoring.
Direct competitors
Company Projected Revenue argenx SE (ARGX)|biontech.de - Company Revenue Forecast|Projected Sales Volume ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Company Expected Sales Volume|Protagonist Therapeutics Inc - Projected Sales Volume|IMVT: Company Projected Revenue|KNSA: Projected Sales Volume|GRFS - Company Future Sales|Company Projected Revenue Adaptive Biotechnologies Corporation|Company Expected Sales Volume Celldex Therapeutics Inc CLDX|Projected Sales Volume AUPH|Company Future Sales Volume Vera Corp VERA|Company Projected Revenue Dianthus Therapeutics DNTH|Company Future Revenue PHVS|ABCL: Company Future Sales Volume|Company Expected Sales Volume Tourmaline Bio Inc|Intrexon (PGEN) - Company Projected Revenue|PHAR - Company Future Sales|Company Future Sales Volume NKTR|UPB (upstreambio.com) - Company Projected Revenue Volume|Projected Sales Volume ZBIO|Company Projected Revenue IMNM (Immunome Inc)|Projected Sales Volume GOSS (Gossamer Corp)|KALV - Company Future Sales Volume|SEPN - Company Projected Revenue|Company Future Revenue PVLA (pieris.com)|SVRA (Savara) - Company Future Sales Volume|Company Revenue Forecast RIGL|Company Projected Revenue AnaptysBio Corp|Astria Corp - Company Expected Revenue|Projected Sales Volume ENGN|RAPT (rapt.com) - Company Future Revenue|Projected Sales Volume JBIO (Aerovate Therapeutics)|Projected Sales Volume Aclaris Therapeutics Inc. ACRS|KYTX - Company Projected Revenue|Company Future Revenue TLSA (Tiziana Life Sciences, Ltd.)|Cabaletta Bio, Inc. (CABA) - Company Projected Revenue|Company Future Sales Volume ventyxbio.com|THTX (Theratechnologies) - Projected Sales Volume|Projected Sales Volume Avalo Therapeutics, Inc.|Company Future Sales Volume ELDN (Eledon)|AGEN (Agenus, Inc) - Company Future Revenue|Projected Sales Volume CLYM (Climb Bio Inc)|Company Future Sales zurabio.com (ZURA)|ATYR - Company Projected Revenue|Adagene (ADAG) - Company Future Sales Volume|ikenaoncology.com (IMA) - Company Projected Revenue|Company Future Sales Volume Shattuck Labs|Company Future Sales Volume EQ|Projected Sales Volume Connect Pharma|Company Projected Revenue Immunic, Inc. (IMUX)|atarabio.com - Company Revenue Forecast|Projected Sales Volume IFRX (InflaRx)|X4 Pharmaceuticals, Inc (XFOR) - Company Expected Sales Volume|Adicet - Projected Sales Volume|CELU: Company Projected Revenue|INMB: Projected Sales Volume|BRNS - Company Future Sales|Company Projected Revenue Kezar Life Sciences, Inc|Company Expected Sales Volume SAB Biotherapeutics Inc SABS|Projected Sales Volume AKTX|Company Future Sales Volume enlivex.com ENLV|Company Projected Revenue Q32 Bio QTTB|Company Future Revenue GOVX|EDSA: Company Future Sales Volume|Company Expected Sales Volume iBio Corporation|carismatx.com (CARM) - Company Projected Revenue|XTLB - Company Future Sales|Company Future Sales Volume BOLT|HCWB (HCW Biologics Inc) - Company Projected Revenue Volume|Projected Sales Volume APVO|Company Projected Revenue AIM (aimimmuno.com)|Projected Sales Volume ADTX (Aditxt, Inc.)|GRI - Company Future Sales Volume|XRTX - Company Projected Revenue|Company Future Revenue HIND (Vyome Holdings Inc.)|REVB (Revelation Bio) - Company Future Sales Volume|Company Revenue Forecast INDP|Company Projected Revenue Scinai Immunotherapeutics|CalciMedica Corp - Company Expected Revenue|Projected Sales Volume AFMD|ALLK (allakos.com) - Company Future Revenue|Projected Sales Volume HOOK (HOOKIPA Pharma)|Projected Sales Volume IGM Biosciences Inc. IGMS|ITOS - Company Projected Revenue|Company Future Revenue OCEA (oceanbiomedical.com)|TC BioPharm (TCBP) - Company Projected Revenue|Company Future Sales Volume Third Harmonic Bio Inc.
